CD274 and non-small cell lung carcinoma: Furthermore, a phase Ib/II, multicenter, open-label trial (NCT06162572) is underway to evaluate the efficacy of the combination therapy of cemiplimab with S095018 (αTIM-3) in treatment-naïve advanced NSCLC patients with high PD-L1 expression.